Final Height Outcome in Girls with Turner Syndrome Treated with Growth Hormone and Low Dose Estrogen

We reported final height data of collected 28 cases with Turner Syndrome (TS) were confirmed chromosomal analysis during growth hormone therapy and late estrogen therapy. Participants allocated into one 3 Groups, Group A: 11 patients aged between 15-18 years-old, group B: 10 -15 C: 7 younger than years-old. In contrast to the duration & presentation, B showed a significantly higher mean (147.5 ±6.5 cm) best result well be obtained in treated high doses for longer period. Records female TS by karyotype examined; 15 had typical 13 indicative variations. Four sixteen individuals variations lacked clinical stigmata associated Syndrome; other nine or more usual TS. Two who complicated mosaic also possessed Y chromosome. Three classics coarctation aorta patient variants 5 primary hypothyroidism received levothyroxine. two pts has hyperthyroidism. syndrome (TS), Growth Hormone (GH) treatment promotes adult height. The benefit-risk ratio supplementing GH weak androgen oxandrolone (Ox) is undefined. administered (1.33 mg/kg/d) from age 8 years-old while estrogens initiated at 12 increase (adult minus predicted height) safety factors evaluated systematic manner.